BerGenBio ASA Statistics
Total Valuation
BerGenBio ASA has a market cap or net worth of NOK 46.75 million. The enterprise value is -22.76 million.
Market Cap | 46.75M |
Enterprise Value | -22.76M |
Important Dates
The last earnings date was Wednesday, August 20, 2025.
Earnings Date | Aug 20, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
BerGenBio ASA has 39.09 million shares outstanding. The number of shares has increased by 35.14% in one year.
Current Share Class | 39.09M |
Shares Outstanding | 39.09M |
Shares Change (YoY) | +35.14% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 6.50% |
Owned by Institutions (%) | 5.68% |
Float | 23.15M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 8.65 |
PB Ratio | 0.70 |
P/TBV Ratio | 0.70 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | 0.21 |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.39
Current Ratio | 4.39 |
Quick Ratio | 4.19 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -161.26 |
Financial Efficiency
Return on equity (ROE) is -88.81% and return on invested capital (ROIC) is -59.49%.
Return on Equity (ROE) | -88.81% |
Return on Assets (ROA) | -47.22% |
Return on Invested Capital (ROIC) | -59.49% |
Return on Capital Employed (ROCE) | -172.08% |
Revenue Per Employee | 772,143 |
Profits Per Employee | -15.37M |
Employee Count | 13 |
Asset Turnover | 0.04 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.34% in the last 52 weeks. The beta is 1.20, so BerGenBio ASA's price volatility has been higher than the market average.
Beta (5Y) | 1.20 |
52-Week Price Change | -89.34% |
50-Day Moving Average | 1.24 |
200-Day Moving Average | 4.18 |
Relative Strength Index (RSI) | 50.67 |
Average Volume (20 Days) | 90,656 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BerGenBio ASA had revenue of NOK 5.41 million and -107.58 million in losses. Loss per share was -2.75.
Revenue | 5.41M |
Gross Profit | 5.41M |
Operating Income | -115.30M |
Pretax Income | -107.58M |
Net Income | -107.58M |
EBITDA | -115.28M |
EBIT | -115.30M |
Loss Per Share | -2.75 |
Balance Sheet
The company has 69.51 million in cash and n/a in debt, giving a net cash position of 69.51 million or 1.78 per share.
Cash & Cash Equivalents | 69.51M |
Total Debt | n/a |
Net Cash | 69.51M |
Net Cash Per Share | 1.78 |
Equity (Book Value) | 67.00M |
Book Value Per Share | 1.71 |
Working Capital | 66.93M |
Cash Flow
Operating Cash Flow | -137.83M |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross Margin | 100.00% |
Operating Margin | -2,133.21% |
Pretax Margin | -1,990.45% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
BerGenBio ASA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -35.14% |
Shareholder Yield | n/a |
Earnings Yield | -230.14% |
FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on May 30, 2024. It was a reverse split with a ratio of 0.01.
Last Split Date | May 30, 2024 |
Split Type | Reverse |
Split Ratio | 0.01 |
Scores
BerGenBio ASA has an Altman Z-Score of 4.51 and a Piotroski F-Score of 1.
Altman Z-Score | 4.51 |
Piotroski F-Score | 1 |